Toward this end, the adipose-selective activation of Nrf2 in adult mice may limit the unwanted side-effects and improve the clinical outcomes for the treatment of obesity and glucose metabolism by increasing the energy expenditure. The gene discussed is NFE2L2; the disease is obesity due to melanocortin 4 receptor deficiency.